ER+/HER2- Early Breast Cancer

3 total trials 2 recruiting

Filter these 3 trials by phase, country, sponsor and more.

Open in Search →

Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting

2025-522484-15-00 5 2026-04-27
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 5 2024-03-25
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Recruitment ended

2022-501024-20-00 5 2023-07-25

Showing 1–3 of 3 trials